Home/MitoSense/Rick Waldo

RW

Rick Waldo

Board Member

Therapeutic Areas

Neurodegenerative Diseases

MitoSense Pipeline

Drug	Indication	Phase
MOT™ for ALS	Amyotrophic Lateral Sclerosis (ALS)	Pre-clinical
MOT™ Platform	Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Multiple Sclerosis	Research/Discovery

Leadership Team at MitoSense

Brent Segal, PhD

Chief Executive Officer

Catherine Baucom, MD, PhD

Chief Medical Officer

Xian Peng Jiang

Chief Scientific Officer

View full MitoSense profile